Medpace Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: seekingalpha
- Cancellation Rate Increase: In Q1 2026, Medpace experienced a rise in cancellations, with backlog cancellations reaching the highest point in over a year, resulting in a net book-to-bill ratio of 0.88, indicating weakened market demand that could impact future revenue growth.
- Financial Performance: The company reported revenue of $706.6 million and net income per diluted share of $4.28 for the first quarter, while generating $151.8 million in cash flow from operating activities; however, the rising cancellation rate poses challenges to future revenue visibility, leading management to maintain unchanged guidance for 2026.
- Leadership Change: CEO Troendle announced that Jesse Geiger will depart, with Troendle resuming the role of President, a shift that may influence the company's strategic direction and execution capabilities moving forward.
- Market Outlook Uncertainty: While management remains optimistic about approximately $1.94 billion of backlog converting to revenue in the next 12 months, concerns over the ongoing rise in cancellation rates and risks associated with client mergers could adversely affect the company's long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 508.460
Low
462.00
Averages
569.17
High
660.00
Current: 508.460
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Q1 2026 Earnings Call Insights
- Cancellation Rate Increase: In Q1 2026, Medpace experienced a rise in cancellations, with backlog cancellations reaching the highest point in over a year, resulting in a net book-to-bill ratio of 0.88, indicating weakened market demand that could impact future revenue growth.
- Financial Performance: The company reported revenue of $706.6 million and net income per diluted share of $4.28 for the first quarter, while generating $151.8 million in cash flow from operating activities; however, the rising cancellation rate poses challenges to future revenue visibility, leading management to maintain unchanged guidance for 2026.
- Leadership Change: CEO Troendle announced that Jesse Geiger will depart, with Troendle resuming the role of President, a shift that may influence the company's strategic direction and execution capabilities moving forward.
- Market Outlook Uncertainty: While management remains optimistic about approximately $1.94 billion of backlog converting to revenue in the next 12 months, concerns over the ongoing rise in cancellation rates and risks associated with client mergers could adversely affect the company's long-term growth potential.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting investor concerns over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the projected book-to-bill ratio for Q4 2025 was overstated, which may have misled investors regarding the company's financial health and impacted stock prices.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting market disappointment and shaken investor confidence in the company's performance.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, demonstrating the legal mechanisms in place to protect investor rights.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
US Stocks Dip Slightly as Software Sector Weighs Down Market
- Market Weakness: The S&P 500 index fell by 0.07%, the Dow Jones Industrial Average by 0.36%, and the Nasdaq 100 by 0.03%, reflecting investor concerns over stalled peace talks with Iran, which may undermine market confidence.
- Software Sector Decline: ServiceNow dropped over 15% following disappointing earnings, while IBM fell more than 7% due to underwhelming software performance, contributing to broader market pressure and highlighting challenges within the tech sector.
- Mixed Economic Data: Weekly initial unemployment claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April manufacturing PMI increased to 54.0, surpassing forecasts and suggesting ongoing expansion in manufacturing.
- Rising Oil Prices Impact: WTI crude oil prices increased by nearly 1% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and raising inflation expectations, which could further influence bond yields.
See More
Medpace Q1 2026 Earnings Call Insights
- Cancellation Rate Increase: In Q1 2026, Medpace experienced a rise in cancellations, with backlog cancellations reaching the highest point in over a year, resulting in a net book-to-bill ratio of 0.88, indicating weakened market demand that could impact future revenue growth.
- Financial Performance: The company reported revenue of $706.6 million and net income per diluted share of $4.28 for the first quarter, while generating $151.8 million in cash flow from operating activities; however, the rising cancellation rate poses challenges to future revenue visibility, leading management to maintain unchanged guidance for 2026.
- Leadership Change: CEO Troendle announced that Jesse Geiger will depart, with Troendle resuming the role of President, a shift that may influence the company's strategic direction and execution capabilities moving forward.
- Market Outlook Uncertainty: While management remains optimistic about approximately $1.94 billion of backlog converting to revenue in the next 12 months, concerns over the ongoing rise in cancellation rates and risks associated with client mergers could adversely affect the company's long-term growth potential.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, highlighting investor concerns over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false or misleading statements during the class period, failing to disclose that the projected book-to-bill ratio for Q4 2025 was overstated, which may have misled investors regarding the company's financial health and impacted stock prices.
- Performance Decline Impact: On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, significantly below the company's guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting market disappointment and shaken investor confidence in the company's performance.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, demonstrating the legal mechanisms in place to protect investor rights.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Gossamer Bio Lawsuit: A class action lawsuit against Gossamer Bio alleges that during the period from June 16, 2025, to February 20, 2026, the company made materially false statements, misleading investors about the failure of its clinical trial to meet primary endpoints, which could significantly impact stock prices.
- New Era Energy Issues: The class action against New Era Energy reveals that from November 6, 2024, to December 29, 2025, the company overstated its progress on its Texas data center project and was involved in fraudulent activities, potentially leading to substantial financial losses for investors.
- Medpace Holdings Risks: Medpace Holdings is accused of misrepresenting its projected book-to-bill ratio from April 22, 2025, to February 9, 2026, failing to disclose the impact of order cancellations on its financial health, which may mislead investors regarding the company's prospects.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in the aforementioned companies to contact legal counsel promptly to understand their rights and ensure they participate in the class actions effectively.
See More
US Stocks Dip Slightly as Software Sector Weighs Down Market
- Market Weakness: The S&P 500 index fell by 0.07%, the Dow Jones Industrial Average by 0.36%, and the Nasdaq 100 by 0.03%, reflecting investor concerns over stalled peace talks with Iran, which may undermine market confidence.
- Software Sector Decline: ServiceNow dropped over 15% following disappointing earnings, while IBM fell more than 7% due to underwhelming software performance, contributing to broader market pressure and highlighting challenges within the tech sector.
- Mixed Economic Data: Weekly initial unemployment claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April manufacturing PMI increased to 54.0, surpassing forecasts and suggesting ongoing expansion in manufacturing.
- Rising Oil Prices Impact: WTI crude oil prices increased by nearly 1% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and raising inflation expectations, which could further influence bond yields.
See More
